We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Apollo Hospitals Opens New Diabetes Clinics

By HospiMedica International staff writers
Posted on 16 Oct 2014
Print article
Apollo Hospitals (Kolkata, India) has partnered with pharmaceutical giant Sanofi (Paris, France) to improve access to treatment for diabetics.

The joint venture, to be named Apollo Sugar Clinics, will be a subsidiary of Apollo Health and Lifestyle, with Sanofi proposing to buy a 20% stake. For the first phase of the venture, Apollo is in the process of establishing 50 clinics within the next two months, up from 28 at present. The clinics, pitched as a one-stop shop for diabetics, will offer packages to better manage the disease through higher medicine compliance, dietary and exercise regimens, and other lifestyle changes to better manage diabetes related complications.

“Over the years, Apollo Hospitals has benchmarked global best practices in quality healthcare delivery with stringent alignment to approved standards and protocols,” said Prathap Reddy, MD, chairman of Apollo Hospitals Group. “With the increasing burden of diabetes in our society, we need to act quickly and with a sense of purpose to arrest the disease from claiming more lives.”

“Sanofi has a heritage of nearly 100 years in developing treatments for diabetes and understands the impact that local expertise and innovative care models can have for patients who are managing their diabetes,” said Christopher Viehbacher, CEO of Sanofi. “We do clinical research in diabetes globally and can come up with the best medicines and products to manage or treat a medical condition. But this [the sugar clinics] will give us that context to try out evidence based approach in healthcare and find out ways to provide better healthcare at reduced costs.”

India is estimated to have over 65 million people with diabetes and 77.2 million people diagnosed as being pre-diabetics. An average diabetic in urban India spends about INR 30,000 (USD 500) per year on treatment, and the cost of late diagnosis of diabetes can mean the patient end up spending 10–18 times higher.

Sanofi has already attempted to enter the Indian diabetes market in 2013, when it launched the All Star, a low-cost, reusable insulin pen device that was developed to suit Indian conditions.

Related Links:

Apollo Hospitals
Sanofi


Gold Member
12-Channel ECG
CM1200B
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Antimicrobial Barrier Dressing
ACTICOAT FLEX
New
Digital Radiography System
DigiEye 680

Print article

Channels

Surgical Techniques

view channel
Image: Graphical abstract; Surgical field during endomyocardial biopsy and fluoroscopic images (Photo courtesy of Heart Rhythm, DOI: 10.1016/j.hrthm.2024.10.069)

Novel Method Combining Heart Biopsy and Device Implantation Reduces Complications Risk

Endomyocardial biopsy (EMB) is a crucial diagnostic tool for identifying various cardiac conditions; however, it carries a risk of complications due to its invasive nature. New research has introduced... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.